Valneva's Lyme Vaccine Shows 70% Efficacy, Misses Primary Endpoint in Phase 3 Trial

Valneva's Lyme disease vaccine candidate demonstrated more than 70% efficacy in a Phase 3 trial, but missed a primary endpoint due to fewer Lyme cases than expected. The vaccine targets outer surface protein A on the Lyme-causing Borrelia bacteria and is the first human Lyme disease vaccine available in decades. Pfizer plans to move forward with regulatory submissions, citing the strong efficacy and safety profile.